Key Takeaways
- • Blackstone and TPG are acquiring Hologic for $18.3 billion in an all-cash take-private transaction at $76 per share, with potential earnout consideration up to $3 per share tied to revenue targets.
- • The transaction has secured debt financing commitments from Citi, Bank of America, Barclays, Royal Bank of Canada, and SMBC, plus equity commitments from both PE firms' balance sheets sufficient to cover the full purchase price and related fees.
- • Deal closure is expected in H1 2026 subject to stockholder approval, regulatory clearance, and customary closing conditions; Hologic's board has granted unanimous approval and recommended shareholder endorsement.
- • Hologic will be delisted from Nasdaq upon completion but will maintain its Massachusetts headquarters, operate under the same brand, and preserve its identity as a women's health and medical diagnostics leader.
- • The merger is subject to a 45-day "go shop" period allowing Hologic's board to solicit and negotiate with third-party bidders; no superior bid guarantees exist and Hologic will not disclose updates unless a superior proposal emerges.
Summary
Blackstone and TPG have agreed to acquire Hologic, the medical diagnostics and breast imaging company, in a take-private transaction valued at up to $18.3 billion. Under the terms announced on Tuesday, the two private equity firms will pay $76 per share in cash for all outstanding shares, with potential earnout consideration of up to $3 per share contingent on revenue targets. The deal represents a strategic entry by major PE capital into the medtech diagnostic imaging sector, reflecting continued appetite for consolidation in healthcare technology.
The financing structure demonstrates substantial backing from both sponsors and the banking syndicate. Blackstone and TPG have obtained committed debt financing letters from Citi, Bank of America, Barclays, Royal Bank of Canada, and SMBC. Additionally, equity commitments from funds advised by both firms—including Blackstone's private equity strategy for individual investors and TPG Capital, its U.S. and European PE platform—are stated to be sufficient to fund the purchase price and all related transaction expenses at closing. This dual commitment of debt and equity financing provides deal certainty, a critical requirement for institutional investors evaluating PE acquisition activity.
The transaction carries standard closing conditions and is targeted for completion in the first half of 2026 pending stockholder approval and regulatory clearance. Hologic's board of directors has provided unanimous approval and is recommending shareholder endorsement. Ram Jagannath, a senior managing director at Blackstone, characterized Hologic as "an outstanding global leader in advancing women's health, with a longstanding reputation for groundbreaking and high-quality medical device and diagnostic products," signaling the sponsors' confidence in the asset quality and operational runway.
Structurally, the merger incorporates a 45-day "go shop" period that permits Hologic and its advisors to solicit and negotiate with third-party bidders. The company's board retains the right to terminate the merger agreement and accept a superior proposal. However, all parties have emphasized that no assurance exists that this process will produce a higher bid, and Hologic does not plan to disclose updates unless a superior proposal materializes. Upon deal completion, Hologic's common stock will be delisted from Nasdaq; the company will continue operating under its current name and brand with its Massachusetts headquarters intact. Hologic was advised by Goldman Sachs, Skadden Arps Slate Meagher & Flom, Wachtell Lipton Rosen & Katz, and Brunswick Group on the transaction.
The financing structure demonstrates substantial backing from both sponsors and the banking syndicate. Blackstone and TPG have obtained committed debt financing letters from Citi, Bank of America, Barclays, Royal Bank of Canada, and SMBC. Additionally, equity commitments from funds advised by both firms—including Blackstone's private equity strategy for individual investors and TPG Capital, its U.S. and European PE platform—are stated to be sufficient to fund the purchase price and all related transaction expenses at closing. This dual commitment of debt and equity financing provides deal certainty, a critical requirement for institutional investors evaluating PE acquisition activity.
The transaction carries standard closing conditions and is targeted for completion in the first half of 2026 pending stockholder approval and regulatory clearance. Hologic's board of directors has provided unanimous approval and is recommending shareholder endorsement. Ram Jagannath, a senior managing director at Blackstone, characterized Hologic as "an outstanding global leader in advancing women's health, with a longstanding reputation for groundbreaking and high-quality medical device and diagnostic products," signaling the sponsors' confidence in the asset quality and operational runway.
Structurally, the merger incorporates a 45-day "go shop" period that permits Hologic and its advisors to solicit and negotiate with third-party bidders. The company's board retains the right to terminate the merger agreement and accept a superior proposal. However, all parties have emphasized that no assurance exists that this process will produce a higher bid, and Hologic does not plan to disclose updates unless a superior proposal materializes. Upon deal completion, Hologic's common stock will be delisted from Nasdaq; the company will continue operating under its current name and brand with its Massachusetts headquarters intact. Hologic was advised by Goldman Sachs, Skadden Arps Slate Meagher & Flom, Wachtell Lipton Rosen & Katz, and Brunswick Group on the transaction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.